Paul L. Berns, President and CEO at Anacor Pharmaceuticals, Inc. (ANAC), sold 37,500 shares at $56.07 ($2.1M) on 2015-03-19, disclosed to the SEC on 2015-03-23.
Scheduled sale ($2.1M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |